Germany’s health minister has given regulatory approval for the first trial in the country of a vaccine for the coronavirus.
Jens Spahn says the trial will involve 200 people ages 18-55. He cautions the process of fully testing the vaccine would take months.
Germany’s regulatory authority, the Paul Ehrlich Institute, approved the trial for an RNA-based vaccine being jointly developed by BioNTech and Pfizer. Regulatory approval for trials is also being sought in the United States and China.
Numerous companies are racing to develop a vaccine for the coronavirus that has infected more than 2.5 million people worldwide and caused at least 178,000 deaths in the past four months.